Professor Clare Scott holds the Chair in Gynaecological Cancer at the University of Melbourne and is Joint Division Head of Clinical Translation and a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research and Medical Oncologist at the Peter MacCallum Cancer Centre, Royal Women’s and Royal Melbourne Hospitals. She has 25 years’ experience in clinical cancer genetics, including working in Familial Cancer Clinics. Her clinical expertise is in gynaecological cancers and coordinating care for patients with rare cancers. Her laboratory focuses on drug resistance in ovarian cancer and other rare cancer types, generating patient-specific models to understand and avert resistance to targeted therapeutics. In particular, she has been a leader in developing PARP inhibitor therapy for ovarian cancer, which has resulted in unprecedented efficacy. Professor Scott chairs the COSA Rare Cancer group and the Board of the International Rare Cancer Initiative (IRCI). She is also the Chair of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG). Prof Scott has been awarded Clinical Fellowships from the Victorian Cancer Agency (2011, 2017), the Sir Edward Dunlop Cancer Research Fellowship from the Cancer Council Victoria (2012) and in 2018, the Jeannie Ferris Recognition Award in Gynaecological Cancer from Cancer Australia. In 2021, she was awarded the MOGA Novartis Oncology Cancer Achievement Award. She is a Fellow of the Australian Academy of Health and Medical Sciences. In 2022, Professor Scott was appointed a Member of the Order of Australia (AM) for significant service to gynaecological oncology.